Opus Genetics vs Entrada Therapeutics
IRD and TRDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IRD and TRDA compare
Opus Genetics is the larger company, worth 1.7 times as much as Entrada Therapeutics ($359M against $212M).
Opus Genetics grew revenue faster over the last twelve months (−45.9% versus −93.5% for Entrada Therapeutics).
Opus Genetics keeps more of each dollar of sales as profit, with a net margin of −1727% compared with −4058% at Entrada Therapeutics.
Entrada Therapeutics scores higher on the StockData Score (6 against 5 for Opus Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IRD | TRDA |
|---|---|---|
| Size and price | ||
| Market cap | $359M | $212M |
| Share price | $4.31 | $5.44 |
| Change, 1 year | 119% | −25.1% |
| Change, 5 years | 18.4% | −83.4% |
| Beta (5Y) | 0.98 | 0.97 |
| Employees | 27 | 152 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 45.3× (better) | 53.3× |
| P/B | 9.3× | 1.1× (better) |
| FCF yield | – | −64.4% |
| Fair value | $0.739 | – |
| Margin of safety | −483% | – |
| Growth | ||
| Revenue growth (TTM) | −45.9% (better) | −93.5% |
| Profitability | ||
| Operating margin | −778% (better) | −4304% |
| Net margin | −1727% (better) | −4058% |
| FCF margin | – | −3428% |
| Return on equity | −616% | −59.9% (better) |
| Return on invested capital | – | −1406% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −217.5× | – |
| Current ratio | 9.65 (better) | 7.85 |
| Altman Z-score | −1.73 | −1.53 (better) |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −0.68% | – |
| Shareholder yield | −0.68% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 72.8% | 75.6% |
| Held by insiders | 37.6% | 14.8% |
| Insider net buying, 12 months | −$19.4M | −$11.5M (better) |
| Short interest, % of float | 20.9% | 8.5% |
Go deeper
- IRD stock overview
- IRD income statement
- IRD valuation and score
- TRDA stock overview
- TRDA income statement
- TRDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.